Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3616 in Advanced Breast Cancer
NCT03850873Phase 1Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- May 2019
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of culmerciclib in breast cancer, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Dose-Limiting Toxicity up to 28 days and Maximum Tolerated Dose up to 28 days. Started May 2019; status: completed.
02
Drugs
culmerciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03850873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03850873.